Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
Asociación Colombiana de Diabetes · Diabetes & Glandular Disease Clinic · +1 more institution
Abstract
To examine the efficacy and safety of once-daily oral sitagliptin as monotherapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled study, 741 patients (baseline HbA(1c) [A1C] 8.0%) were randomized to sitagliptin 100 or 200 mg or placebo for 24 weeks.
Sitagliptin 100 and 200 mg produced significant (P or=9% had greater reductions in placebo-subtracted A1C with sitagliptin 100 and 200 mg (-1.52 and -1.50%, respectively) than those with baseline A1C or=8 to
Citation impact
- FWCI
- 42.97
- Percentile
- 100%
- References
- 25
Authors
7- PAPablo AschnerCorresponding
Asociación Colombiana de Diabetes
- MKMark Kipnes
Diabetes & Glandular Disease Clinic
- JLJared Lunceford
Merck & Co., Inc., Rahway, NJ, USA (United States)
- MSMatilde Sanchez
Merck & Co., Inc., Rahway, NJ, USA (United States)
- CMCarolyn Mickel
Merck & Co., Inc., Rahway, NJ, USA (United States)
Topics & keywords
- Sitagliptin
- Sitagliptin Phosphate
- Medicine
- Dipeptidyl peptidase-4 inhibitor
- Postprandial
- Placebo
- Internal medicine
- Glycemic
- Good health and well-being